X
Tackling adherence is “only sustainable path to profit”
https://pharmaphorum.com/views-analysis-sales-marketing/tackling-adherence-is-only-sustainable-path-to-profit/
adherence
Non-adherence: pharma’s final financial frontier
No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.
